24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
During Stress of Pandemic, Know Suicide's Warning SignsEarly Results Show Moderna's COVID Vaccine Safe, Effective in Older PeoplePandemic Has More Americans Turning to BoozeStudy Confirms Minorities Face Higher Odds of COVID-19: StudyLockdown Could Worsen Hearing Woes for U.S. SeniorsGlobal Death Toll From COVID-19 Passes One MillionWarming World Could Alter West Nile Transmission in U.S.Most Newborns of COVID-19-Infected Moms Fare WellCOVID Antibodies Found in Less Than 10% of AmericansCOVID-19 Patients Rarely Survive Cardiac Arrest: StudyLow Vitamin D Levels Tied to Higher Odds for Severe COVIDKids Much Less Prone to Coronavirus Infection Than Adults: Study'Silent' COVID-19 Produces as Much Virus as in Patients With Symptoms: StudyImmune System Clues to Why COVID Is Easier on KidsU.S. Coronavirus Cases Top 7 MillionAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsAmerica's COVID Pandemic Is Now Skewing YoungerEven If Hips, Legs Slim Down, Belly Fat Remains a Health DangerAfter COVID-19 Exposure, When Can Young Athletes Resume Play?Kids Who Need Steroids Face Risk of Diabetes, Other Ills9 in 10 Americans Not Yet Immune to COVID, CDC Director SaysCommon Heart Defect Limits Exercise Ability: StudyBlood Test Could Spot Those at Highest Risk for Severe COVID-19Singing Without a Face Mask Can Spread COVID-19Could Zinc Help Fight COVID-19?U.S. COVID Death Toll Hits 200,000 as Cases Climb in 22 States4 Out of 5 People With COVID-19 Will Develop Symptoms: StudyMany Health Care Workers Who Have Coronavirus Don't Have Symptoms: StudyAHA News: Cluster of Risky Conditions That Can Lead To Heart Disease Is Rising in Hispanic AdultsMinorities Hit Hardest When COVID Strikes Nursing HomesAvoid the 'Twindemic:' Get Your Flu Shot NowCertain Cancer Treatments May Heighten Danger From COVID-19Homemade Masks Do a Great Job Blocking COVID-19Having Flu and COVID Doubles Death Risk in Hospitalized PatientsGuard Yourself Against the Health Dangers of Wildfire SmokeLife Expectancy Could Decline Worldwide Due to COVID-19Potential COVID-19 Drug Could Increase Heart Risk: StudyU.S. COVID Death Toll Nears 200,000, While Cases Start to Climb AgainCDC Reverses COVID Test Guideline After ControversyAs Schools Reopen, Many Students, Staff Live With High-Risk Family MemberCOVID-19 Poses Added Risk for People With Addiction Disorders: StudyGetting a Hip Replacement? Choice of Hospital Can Be CrucialAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportAnother Rapid COVID-19 Test Shows PromiseDetails Emerge on Unexplained Illness in AstraZeneca COVID Vaccine TrialRising Obesity Levels Put Americans at Risk During Pandemic: CDCMore Pets May Be Getting COVID-19 Than RealizedWildfire Smoke Poses Special Threat to People With AsthmaCOVID-19 Prevention Might Translate Into Record Low Flu Rates: CDCFor Stroke Survivors, Timely Rehab Has Been Jeopardized During Pandemic
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves First Oral Drug for Spinal Muscular Atrophy


HealthDay News
Updated: Aug 10th 2020

new article illustration

MONDAY, Aug. 10, 2020 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first oral, at-home drug for spinal muscular atrophy (SMA), the agency announced Friday.

Evrysdi (risdiplam) was approved to treat patients ages 2 months and older with SMA and is the second drug approved for the disease. The drug is administered daily at home by mouth or feeding tube.

Approval was based on two clinical studies, including FIREFISH, an open-label study of 21 patients aged 6.7 months on average at study initiation. At one year, 41 percent of patients met the efficacy end point of sitting independently for more than five seconds, and at nearly two years, 81 percent of patients were alive without permanent ventilation, which the FDA notes is a "noticeable improvement from typical disease development without treatment."

In the second study, SUNFISH, a randomized, placebo-controlled study of 180 patients ages 2 to 25 years, the Motor Function Measure-32 total score increased an average of 1.36 from baseline to one year for patients randomly assigned to Evrysdi compared with a decrease of 0.19 for patients randomly assigned to placebo.

The most commonly reported side effects of Evrysdi were fever, diarrhea, rash, ulcers in the mouth area, arthralgia, and urinary tract infections. Patients with infantile-onset SMA had additional side effects of upper respiratory tract infection, pneumonia, constipation, and vomiting. The FDA warns that patients taking Evrysdi should avoid taking it with drugs that are multidrug and toxin extrusion substrates because Evrysdi may increase plasma concentrations.

Approval was granted to Genentech.

More Information